EVASTENT national registry: Cost-effectiveness evaluation of sirolimus-eluting stent among diabetic and non-diabetic patients;Le registre national EVASTENT: Évaluation coût/ efficacité du stent actif au sirolimus chez les patients diabétiques et non diabétiques

Annales de Cardiologie et d'Angeiologie

Volumn 53, Issue SUPPL. 1, 2004, Pages

  MacHecourt, J ^a   Danchin, N ^b   Lablanche, J M ^c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; RAPAMYCIN;

CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG SCREENING; ENDOPROSTHESIS; HUMAN; RANDOMIZATION; REGISTER; REVIEW; SILENT MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 4043099124     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Morice M.C., Seruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin I.M., et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780
2. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.L., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. SIRIUS Investigators. N Engl J Med. 349:2003;1315-1323
3. Holmes D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial : a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 109:2004;634-640
4. Schofer J., Schluter M., Gershlick A.H., Wijns W., Garcia E., Schampaert E., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries : double-blind, randomised controlled trial (E-SIRIUS). E-SIRIUS Investigators. Lancet. 362:2003;1093-1099
5. Weintraub W.S., Ghazzal Z.M., Douglas J.S., Liberman H.A., Morris D.C., Cohen C.L., et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 87:1993;831-840
6. Greenberg D., Bakhai A., Cohen D.J. Can we afford to eliminate restenosis ? Can we afford not to? J Am Coll Cardiol. 43:2004;513-518
7. Cutlip D.E., Chauhan M.S., Baim D.S., Ho K.K., Poma J.J., Carrozza J.P., et al. Clinical restenosis after coronary stenting : perspectives from multicenter clinical trials. J Am Coll Cardiol. 40:2002;2082-2090
8. Mark D.B., Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine. Part I. Circulation. 106:2002;516-520
9. Chumer K., DeCerce J., Vaul J. Managing technological explosion in the medical management of coronary artery disease. Part II. DES economic modeling : budgeting strategies for drug-eluting stent technology. J Cardiovasc Manag. 13:2002;16-20
10. van Hout B.A., Lindeboom W.K., Morice M.C., et al. Cost-effectiveness of the sirolimus eluting bx-VELOCITY stent : I -year results. [abstract] Eur Heart J. 23:(Suppl 691):2002
11. Cohen D.J., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus drug eluting. [abstract] J Am Coll Cardiol. 41:2003;32A. Suppl : 32A
12. O'Neill W.W., Leon M.B. Drug-eluting stents : costs versus clinical benefit. Circulation. 107:2003;3008-3011
13. Lemos P.A., Serruys P.W., Sousa J.E. Drug-eluting stents : cost versus clinical benefit. Circulation. 107:2003;3003-3007
14. Bhatt D.L., Bertrand M.E., Berger P.B., L'Allier P.L., Moussa I., Moses J.W., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 39:2002;9-14